Drug intelligence / Profile preview

jing xue bu pian

Development stage: Unknown
Lead developer: Nantong Pharmaceutical Factory
Administration: Oral

Overview

Jing Xue Bu Pian is a traditional Chinese medicine (TCM) tablet developed and manufactured by Nantong Pharmaceutical Factory, a subsidiary of Jinghua Pharmaceutical Group. It is an approved pharmaceutical product in China indicated for the treatment of deficiency of essence and blood (精血不足). The formula is designed to tonify the kidneys and nourish the blood, and it is clinically used to alleviate symptoms such as dizziness, tinnitus, palpitations, insomnia, and weakness or soreness in the lower back and knees. As a multi-herb TCM formulation, it works through the synergistic effects of its constituent botanical ingredients to restore physiological balance according to traditional medical principles.

Brand names: 精血补片
Other names: 精血补片Jing Xue Bu Pian

Beyond the preview

Go deeper on jing xue bu pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jing xue bu pian.

Explore the full profile